secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2021-11-26T23:59:59+00:00
Accession:  0001104659-21-143748
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 2.03, 3.02, 5.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI closes Novitium buy for $89.5M cash + shares; $300M loan & $25M PIPE
------------------------------------------------------------------------

- Consideration: $89.5M cash + 2.47M shares + up to $46.5M earn-out.
- New financing: $300M Term Loan (Truist) + $40M revolver + $25M PIPE from Ampersand.
- Appoints Novitium co-founders: Samy Shanmugam as Head of R&D/COO & director; Chad Gassert as SVP Corp Dev.
- Pro-forma YTD Sep 30 revenue $202.5M; non-GAAP EBITDA $66.6M; immediately accretive to adj. EPS.
- Novitium pipeline: 20+ launches in 18 months, 13 approvals since March 2021, including CGT products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/0001104659-21-143748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/tm2133555d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-143748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer